epinephrine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sympathomimetic, phenethyl derivatives 1028 51-43-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • epinephrine
  • vasoconstrictine
  • nephridine
  • renoform
  • suprarenin
  • epinephrine bitartrate
  • (-)-adrenaline
  • epinephrine hydrochloride
The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.
  • Molecular weight: 183.21
  • Formula: C9H13NO3
  • CLOGP: -0.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -0.99
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg P
2.24 mg Inhal.aerosol
20 mg Inhal.solution

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.09 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 1948 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sinusitis 621.56 9.77 1123 98728 167441 53081774
Hereditary angioedema 524.32 9.77 249 99602 6004 53243211
Anaphylactic reaction 492.29 9.77 576 99275 57750 53191465
Stress cardiomyopathy 436.70 9.77 244 99607 8318 53240897
Anaesthetic complication 366.76 9.77 138 99713 1816 53247399
Local anaesthetic systemic toxicity 332.84 9.77 96 99755 500 53248715
Device failure 316.04 9.77 176 99675 5959 53243256
Toxic anterior segment syndrome 264.88 9.77 115 99736 2233 53246982
Cardiac arrest 260.62 9.77 555 99296 93112 53156103
Accidental exposure to product 255.31 9.77 266 99585 23408 53225807
Rheumatoid arthritis 254.45 9.77 136 99715 314395 52934820
Anaphylactic shock 243.31 9.77 250 99601 21643 53227572
Infusion site swelling 212.83 9.77 143 99708 6811 53242404
Infusion site erythema 199.80 9.77 151 99700 8671 53240544
Infusion site pain 188.61 9.77 165 99686 11668 53237547
Contraindicated product administered 185.87 9.77 19 99832 135610 53113605
Drug intolerance 171.75 9.77 85 99766 205408 53043807
Pulseless electrical activity 169.72 9.77 128 99723 7326 53241889
Pemphigus 168.01 9.77 6 99845 104025 53145190
Joint swelling 153.85 9.77 128 99723 234510 53014705
Chondrolysis 152.86 9.77 42 99809 177 53249038
Incorrect route of product administration 139.33 9.77 176 99675 19068 53230147
Bradycardia 138.80 9.77 367 99484 70689 53178526
Upper respiratory tract infection 136.10 9.77 358 99493 68739 53180476
Systemic lupus erythematosus 135.24 9.77 34 99817 125380 53123835
Lagophthalmos 135.22 9.77 41 99810 261 53248954
Bronchitis 134.62 9.77 488 99363 111411 53137804
Hand deformity 133.27 9.77 6 99845 84843 53164372
Completed suicide 130.04 9.77 48 99803 138153 53111062
Infusion site pruritus 128.68 9.77 83 99768 3687 53245528
Hypotension 127.61 9.77 863 98988 253213 52996002
Infusion site extravasation 122.29 9.77 98 99753 6134 53243081
Glossodynia 120.85 9.77 21 99830 100270 53148945
Alopecia 118.95 9.77 159 99692 234424 53014791
Ventricular tachycardia 118.49 9.77 156 99695 17606 53231609
Urticaria 115.34 9.77 532 99319 135353 53113862
Kounis syndrome 112.17 9.77 53 99798 1262 53247953
Administration site swelling 107.64 9.77 50 99801 1144 53248071
Synovitis 107.51 9.77 34 99817 107859 53141356
Abdominal discomfort 101.11 9.77 161 99690 220901 53028314
Hepatic enzyme increased 99.76 9.77 56 99795 126139 53123076
Cardiogenic shock 91.96 9.77 137 99714 17345 53231870
Maternal exposure during delivery 91.07 9.77 43 99808 1022 53248193
Infusion site nodule 90.94 9.77 44 99807 1106 53248109
Ear infection 90.60 9.77 169 99682 25731 53223484
Corneal oedema 88.46 9.77 51 99800 1846 53247369
General physical health deterioration 88.07 9.77 87 99764 146855 53102360
Arthropathy 87.99 9.77 81 99770 141372 53107843
Product quality issue 84.58 9.77 203 99648 36820 53212395
Headache 84.34 9.77 1441 98410 535380 52713835
Shock 83.47 9.77 153 99698 22986 53226229
Infusion site bruising 83.23 9.77 51 99800 2068 53247147
Bronchospasm 81.53 9.77 126 99725 16472 53232743
Fear 79.89 9.77 125 99726 16516 53232699
Pericarditis 78.65 9.77 13 99838 64393 53184822
Angioedema 77.78 9.77 213 99638 41863 53207352
Anhedonia 77.77 9.77 98 99753 10589 53238626
Administration site pain 77.24 9.77 34 99817 683 53248532
Left ventricle outflow tract obstruction 76.50 9.77 26 99825 249 53248966
Wound 76.22 9.77 38 99813 91519 53157696
Renal injury 75.56 9.77 93 99758 9811 53239404
Ventricular fibrillation 75.34 9.77 102 99749 11823 53237392
Arthralgia 74.90 9.77 499 99352 439284 52809931
Drug ineffective 74.56 9.77 2027 97824 815218 52433997
Injection site pallor 72.07 9.77 18 99833 47 53249168
Injection site ischaemia 71.25 9.77 14 99837 3 53249212
Injury associated with device 70.52 9.77 54 99797 3161 53246054
Methaemoglobinaemia 70.19 9.77 47 99804 2225 53246990
Administration site erythema 69.83 9.77 30 99821 567 53248648
Tachycardia 68.25 9.77 390 99461 107822 53141393
Electrocardiogram ST segment elevation 66.82 9.77 56 99795 3733 53245482
Therapeutic product effect decreased 65.85 9.77 83 99768 125572 53123643
Stridor 65.76 9.77 53 99798 3344 53245871
Infusion site haemorrhage 65.36 9.77 49 99802 2778 53246437
Expired product administered 65.08 9.77 67 99784 5809 53243406
Cauda equina syndrome 64.37 9.77 31 99820 771 53248444
Diarrhoea 63.42 9.77 809 99042 624737 52624478
Pulse absent 63.34 9.77 63 99788 5243 53243972
Unevaluable event 63.00 9.77 220 99631 49278 53199937
Arteriospasm coronary 62.88 9.77 54 99797 3723 53245492
Peripheral ischaemia 60.84 9.77 59 99792 4760 53244455
Hyponatraemia 59.81 9.77 69 99782 108538 53140677
Airway peak pressure increased 59.19 9.77 22 99829 279 53248936
Endophthalmitis 59.14 9.77 51 99800 3536 53245679
Treatment failure 57.26 9.77 95 99756 128308 53120907
Injury 56.81 9.77 217 99634 50754 53198461
Generalised tonic-clonic seizure 56.58 9.77 149 99702 28609 53220606
Lip swelling 55.64 9.77 143 99708 27058 53222157
Haemodynamic instability 55.04 9.77 74 99777 8520 53240695
Helicobacter infection 54.73 9.77 5 99846 39064 53210151
Acute kidney injury 53.90 9.77 268 99583 253600 52995615
Incorrect drug administration rate 51.43 9.77 40 99811 2396 53246819
Injection site hypoaesthesia 50.80 9.77 21 99830 359 53248856
Neutropenia 50.09 9.77 143 99708 159042 53090173
Cataract operation complication 48.66 9.77 16 99835 137 53249078
Circulatory collapse 48.11 9.77 121 99730 22593 53226622
Anaemia 48.01 9.77 312 99539 276406 52972809
Infusion site mass 47.89 9.77 28 99823 1041 53248174
Hypoaesthesia oral 47.81 9.77 81 99770 11435 53237780
Decreased appetite 47.32 9.77 224 99627 214750 53034465
Electrocardiogram ST segment depression 47.12 9.77 41 99810 2877 53246338
Emotional distress 45.85 9.77 149 99702 32168 53217047
Pharyngeal oedema 45.76 9.77 91 99760 14522 53234693
Folliculitis 44.58 9.77 4 99847 31705 53217510
Vasoplegia syndrome 43.81 9.77 28 99823 1224 53247991
Lower respiratory tract infection 42.74 9.77 65 99786 90916 53158299
Body tinea 42.37 9.77 27 99824 1174 53248041
Infusion site urticaria 42.36 9.77 24 99827 840 53248375
Post procedural complication 42.01 9.77 95 99756 16571 53232644
Seizure 41.88 9.77 398 99453 129111 53120104
Confusional state 41.79 9.77 204 99647 194017 53055198
Nerve block 41.76 9.77 20 99831 491 53248724
Wrong product administered 41.70 9.77 54 99797 5994 53243221
Respiratory tract infection 41.69 9.77 147 99704 33077 53216138
Pulmonary oedema 41.64 9.77 205 99646 53518 53195697
Unresponsive to stimuli 41.18 9.77 147 99704 33279 53215936
Administration site pruritus 40.23 9.77 17 99834 308 53248907
Migraine 40.14 9.77 273 99578 80144 53169071
Ventricular hypokinesia 39.56 9.77 45 99806 4367 53244848
Paraesthesia oral 39.46 9.77 80 99771 12945 53236270
Ophthalmoplegia 38.92 9.77 25 99826 1102 53248113
Muscle injury 38.67 9.77 5 99846 29761 53219454
Procedural hypotension 38.52 9.77 26 99825 1247 53247968
Laryngeal oedema 38.30 9.77 50 99801 5595 53243620
Pancytopenia 38.05 9.77 70 99781 90858 53158357
Abortion spontaneous 37.84 9.77 20 99831 46615 53202600
Infusion site irritation 37.77 9.77 20 99831 611 53248604
Troponin I increased 37.57 9.77 31 99820 2022 53247193
Tryptase increased 37.37 9.77 15 99836 237 53248978
Impaired healing 37.31 9.77 39 99812 64166 53185049
Blood creatinine increased 36.99 9.77 61 99790 82601 53166614
Anaesthetic complication neurological 36.94 9.77 14 99837 188 53249027
Needle issue 36.94 9.77 55 99796 6957 53242258
Psoriasis 36.48 9.77 67 99784 87022 53162193
Staphylococcal infection 36.48 9.77 156 99695 38392 53210823
Injection site injury 36.47 9.77 19 99832 561 53248654
Infusion site reaction 36.32 9.77 31 99820 2119 53247096
Infusion site rash 36.24 9.77 24 99827 1115 53248100
Intentional self-injury 36.06 9.77 3 99848 25281 53223934
Extradural haematoma 35.67 9.77 28 99823 1700 53247515
C-reactive protein increased 35.38 9.77 45 99806 67841 53181374
Therapeutic product effect prolonged 34.89 9.77 16 99835 355 53248860
Status asthmaticus 34.87 9.77 22 99829 940 53248275
Mydriasis 34.83 9.77 70 99781 11256 53237959
Liquid product physical issue 34.79 9.77 20 99831 720 53248495
Administration site reaction 34.77 9.77 14 99837 223 53248992
Administration site bruise 34.70 9.77 15 99836 288 53248927
Platelet aggregation inhibition 34.49 9.77 12 99839 124 53249091
Swollen tongue 34.36 9.77 132 99719 30948 53218267
Death 34.22 9.77 467 99384 356765 52892450
Product use issue 33.99 9.77 140 99711 139444 53109771
Blood pressure decreased 33.89 9.77 215 99636 61654 53187561
Drug reaction with eosinophilia and systemic symptoms 33.26 9.77 10 99841 32790 53216425
Leukopenia 33.06 9.77 54 99797 73409 53175806
Asthenia 32.97 9.77 449 99402 343141 52906074
Sinus tachycardia 32.83 9.77 108 99743 23464 53225751
Thrombocytopenia 32.63 9.77 141 99710 138586 53110629
Type I hypersensitivity 32.55 9.77 32 99819 2625 53246590
Administration site extravasation 32.43 9.77 19 99832 709 53248506
Nerve root injury 32.19 9.77 9 99842 41 53249174
Injection site coldness 32.17 9.77 10 99841 70 53249145
Infusion site warmth 32.15 9.77 25 99826 1497 53247718
Procedural complication 32.04 9.77 44 99807 5168 53244047
Hyperaesthesia 32.02 9.77 58 99793 8631 53240584
Peripheral nerve injury 31.92 9.77 16 99835 435 53248780
Anaphylactoid reaction 31.68 9.77 37 99814 3694 53245521
Anaphylactoid shock 30.93 9.77 14 99837 301 53248914
Psoriatic arthropathy 30.65 9.77 27 99824 48163 53201052
Uterine hypertonus 30.54 9.77 13 99838 240 53248975
Cyanosis 30.51 9.77 84 99767 16555 53232660
Asthma 30.45 9.77 325 99526 108647 53140568
Product contamination microbial 30.29 9.77 13 99838 245 53248970
Hypopyon 30.17 9.77 20 99831 931 53248284
C-reactive protein abnormal 29.90 9.77 6 99845 25864 53223351
Anterior chamber cell 29.59 9.77 17 99834 611 53248604
Gas gangrene 29.59 9.77 10 99841 94 53249121
Disease progression 29.58 9.77 95 99756 101825 53147390
Sensory loss 29.43 9.77 53 99798 7852 53241363
Cardiac failure congestive 29.40 9.77 83 99768 92674 53156541
Bursitis infective 29.40 9.77 22 99829 1244 53247971
Extremity necrosis 29.23 9.77 25 99826 1714 53247501
Inadequate analgesia 28.49 9.77 31 99820 2864 53246351
Infusion site discomfort 28.28 9.77 18 99833 781 53248434
Infection susceptibility increased 28.23 9.77 29 99822 2508 53246707
Retinal vasculitis 28.16 9.77 18 99833 787 53248428
Type 2 diabetes mellitus 28.12 9.77 12 99839 31658 53217557
Musculoskeletal stiffness 28.04 9.77 127 99724 123241 53125974
Bladder prolapse 27.92 9.77 26 99825 1994 53247221
Malignant neoplasm progression 27.40 9.77 58 99793 71483 53177732
Myopathy toxic 27.36 9.77 14 99837 398 53248817
Blood pH decreased 27.36 9.77 29 99822 2601 53246614
Impaired quality of life 26.81 9.77 39 99812 4832 53244383
Eyelid rash 26.78 9.77 9 99842 83 53249132
Chills 26.69 9.77 307 99544 104541 53144674
Injection site inflammation 26.68 9.77 32 99819 3286 53245929
Ventricular extrasystoles 26.46 9.77 64 99787 11660 53237555
Corneal epithelium defect 26.43 9.77 13 99838 339 53248876
Cranial nerve palsies multiple 26.39 9.77 7 99844 25 53249190
Systemic toxicity 26.39 9.77 7 99844 25 53249190
Meningitis chemical 26.14 9.77 10 99841 138 53249077
Neuromuscular block prolonged 26.14 9.77 15 99836 538 53248677
Condition aggravated 26.13 9.77 395 99456 296739 52952476
Liver function test abnormal 25.96 9.77 31 99820 48040 53201175
Throat tightness 25.92 9.77 96 99755 22120 53227095
Loss of personal independence in daily activities 25.59 9.77 58 99793 69757 53179458
Pneumocephalus 25.57 9.77 10 99841 147 53249068
Paralysis 25.35 9.77 55 99796 9329 53239886
Cholestasis 25.27 9.77 11 99840 28684 53220531
Trigemino-cardiac reflex 25.20 9.77 7 99844 31 53249184
Inhibitory drug interaction 25.16 9.77 26 99825 2264 53246951
Heart rate increased 25.13 9.77 250 99601 82065 53167150
Peritonitis 25.13 9.77 5 99846 21682 53227533
Mobility decreased 25.10 9.77 67 99784 76204 53173011
Fear of eating 25.07 9.77 13 99838 380 53248835
PO2 decreased 25.02 9.77 22 99829 1565 53247650
Chest discomfort 24.97 9.77 291 99560 99404 53149811
Anxiety 24.79 9.77 511 99340 196193 53053022
Loss of consciousness 24.57 9.77 324 99527 113888 53135327
Parophthalmia 24.53 9.77 12 99839 309 53248906
Hip arthroplasty 24.04 9.77 11 99840 27851 53221364
Respiratory acidosis 24.00 9.77 43 99808 6345 53242870
Myocardial ischaemia 23.70 9.77 65 99786 12779 53236436
Peripheral swelling 23.66 9.77 259 99592 205849 53043366
Hypoaesthesia eye 23.32 9.77 8 99843 79 53249136
Abdominal pain upper 23.30 9.77 199 99652 166092 53083123
Eye infection 22.52 9.77 54 99797 9784 53239431
Troponin T increased 22.47 9.77 17 99834 977 53248238
Bundle branch block left 22.35 9.77 44 99807 6969 53242246
Delayed recovery from anaesthesia 22.21 9.77 16 99835 853 53248362
Osteonecrosis of jaw 22.10 9.77 21 99830 36125 53213090
Spinal epidural haematoma 22.01 9.77 16 99835 865 53248350
Blood cholesterol increased 21.98 9.77 41 99810 52948 53196267
Rectal prolapse 21.93 9.77 22 99829 1849 53247366
Toxicity to various agents 21.62 9.77 551 99300 219047 53030168
Fungal infection 21.49 9.77 118 99733 32128 53217087
Spinal epidural haemorrhage 21.49 9.77 8 99843 102 53249113
Electrocardiogram T wave inversion 21.29 9.77 30 99821 3609 53245606
Wheezing 21.28 9.77 201 99650 65074 53184141
Vasoconstriction 21.22 9.77 13 99838 527 53248688
PCO2 increased 21.16 9.77 18 99833 1225 53247990
Knee arthroplasty 21.12 9.77 19 99832 33550 53215665
Septic arthritis staphylococcal 21.00 9.77 12 99839 427 53248788
Blood lactic acid increased 20.89 9.77 39 99812 5939 53243276
Pallor 20.88 9.77 98 99753 25084 53224131
Sleep disorder 20.70 9.77 50 99801 58820 53190395
Vitritis 20.65 9.77 16 99835 953 53248262
Removal of foreign body 20.62 9.77 5 99846 11 53249204
Drug ineffective for unapproved indication 20.49 9.77 85 99766 20635 53228580
Jaundice 20.49 9.77 16 99835 30297 53218918
Paraplegia 20.42 9.77 25 99826 2622 53246593
Reversible cerebral vasoconstriction syndrome 20.30 9.77 23 99828 2222 53246993
Harlequin syndrome 20.23 9.77 6 99845 35 53249180
Arterial spasm 20.06 9.77 7 99844 73 53249142
Apnoea 20.06 9.77 45 99806 7808 53241407
Hepatocellular injury 20.05 9.77 16 99835 29970 53219245
Administration site discolouration 19.81 9.77 6 99845 38 53249177
Blister 19.78 9.77 78 99773 78675 53170540
Cystitis 19.69 9.77 153 99698 46835 53202380
Agranulocytosis 19.54 9.77 10 99841 23739 53225476
Fear of death 19.50 9.77 16 99835 1035 53248180
Stomatitis 19.45 9.77 106 99745 98052 53151163
Spinal anaesthesia 19.42 9.77 6 99845 41 53249174
Injection site pain 19.36 9.77 309 99542 113082 53136133
Hypocalcaemia 19.19 9.77 16 99835 29321 53219894
Administration site irritation 19.18 9.77 6 99845 43 53249172
Apnoeic attack 19.17 9.77 10 99841 296 53248919
Fall 19.03 9.77 518 99333 357922 52891293
Discomfort 18.97 9.77 103 99748 95369 53153846
Atonic urinary bladder 18.96 9.77 7 99844 87 53249128
Multiple organ dysfunction syndrome 18.93 9.77 173 99678 55504 53193711
Lung hyperinflation 18.89 9.77 17 99834 1247 53247968
Postresuscitation encephalopathy 18.82 9.77 5 99846 18 53249197
Red blood cell sedimentation rate increased 18.73 9.77 15 99836 28042 53221173
Retinal artery occlusion 18.68 9.77 19 99832 1624 53247591
Neurogenic shock 18.66 9.77 10 99841 313 53248902
Eyelid ptosis 18.61 9.77 39 99812 6458 53242757
Vasospasm 18.59 9.77 13 99838 661 53248554
Mean arterial pressure decreased 18.53 9.77 8 99843 153 53249062
Orthostatic hypotension 18.52 9.77 17 99834 29736 53219479
Supraventricular tachycardia 18.50 9.77 64 99787 14261 53234954
Upper airway obstruction 18.50 9.77 13 99838 666 53248549
Administration site nodule 18.50 9.77 6 99845 49 53249166
Aqueous fibrin 18.47 9.77 7 99844 94 53249121
Anaesthesia oral 18.37 9.77 4 99847 4 53249211
Post-traumatic neuralgia 18.37 9.77 4 99847 4 53249211
Influenza like illness 18.17 9.77 184 99667 60675 53188540
Conjunctival oedema 18.16 9.77 13 99838 686 53248529
Arachnoiditis 18.13 9.77 10 99841 332 53248883
Respiratory depression 18.12 9.77 59 99792 12747 53236468
Accidental overdose 18.11 9.77 84 99767 21395 53227820
Pharyngeal swelling 18.08 9.77 32 99819 4676 53244539
Enzyme induction 17.98 9.77 6 99845 54 53249161
Pharyngitis streptococcal 17.89 9.77 47 99804 9008 53240207
Depressed mood 17.75 9.77 26 99825 36938 53212277
Drug abuse 17.69 9.77 63 99788 65463 53183752
Systolic anterior motion of mitral valve 17.67 9.77 5 99846 24 53249191
Swelling face 17.63 9.77 174 99677 56994 53192221
Interstitial lung disease 17.45 9.77 54 99797 58568 53190647
Pupils unequal 17.42 9.77 17 99834 1382 53247833
Gastroenteritis viral 17.32 9.77 77 99774 19268 53229947
Hepatotoxicity 17.27 9.77 16 99835 27864 53221351
Glossoptosis 17.25 9.77 6 99845 62 53249153
Punctate keratitis 17.25 9.77 12 99839 605 53248610
Kidney infection 17.15 9.77 76 99775 18991 53230224
Distributive shock 17.09 9.77 14 99837 904 53248311
Abdominal pain 16.83 9.77 358 99493 255545 52993670
Epidural haemorrhage 16.81 9.77 7 99844 122 53249093
Diplegia 16.79 9.77 15 99836 1090 53248125
Administration site haemorrhage 16.75 9.77 6 99845 68 53249147
Gastroenteritis 16.72 9.77 14 99837 25602 53223613
Brain injury 16.69 9.77 37 99814 6368 53242847
Diabetes mellitus 16.51 9.77 49 99802 53850 53195365
Uterine hypotonus 16.50 9.77 7 99844 128 53249087
Neoplasm progression 16.47 9.77 19 99832 29900 53219315
Propofol infusion syndrome 16.42 9.77 13 99838 799 53248416
Product measured potency issue 16.31 9.77 7 99844 132 53249083
Procedural haemorrhage 16.27 9.77 22 99829 2547 53246668
Exposure during pregnancy 16.26 9.77 326 99525 124534 53124681
Hypoaesthesia 16.25 9.77 344 99507 132651 53116564
Pain in extremity 16.16 9.77 408 99443 284642 52964573
Left ventricular dysfunction 16.11 9.77 52 99799 11185 53238030
Local reaction 16.09 9.77 11 99840 539 53248676
Vitamin D increased 15.93 9.77 11 99840 548 53248667
ECG signs of myocardial ischaemia 15.87 9.77 6 99845 80 53249135
Procedural pain 15.85 9.77 62 99789 14655 53234560
Cold sweat 15.85 9.77 53 99798 11609 53237606
Axillary nerve injury 15.85 9.77 3 99848 0 53249215
Vth nerve injury 15.85 9.77 3 99848 0 53249215
Vocal cord dysfunction 15.83 9.77 9 99842 317 53248898
Airway complication of anaesthesia 15.81 9.77 8 99843 222 53248993
Gastrointestinal haemorrhage 15.78 9.77 87 99764 80243 53168972
Injection site necrosis 15.71 9.77 16 99835 1370 53247845
Meningitis aseptic 15.67 9.77 29 99822 4386 53244829
White blood cell count decreased 15.67 9.77 153 99698 124322 53124893
Status epilepticus 15.58 9.77 63 99788 15121 53234094
Skin infection 15.56 9.77 56 99795 12726 53236489
Drug resistance 15.56 9.77 9 99842 19953 53229262
Eye infarction 15.50 9.77 5 99846 40 53249175
Blood pressure increased 15.47 9.77 358 99493 140121 53109094
Type IV hypersensitivity reaction 15.47 9.77 22 99829 2670 53246545
Infusion site induration 15.45 9.77 13 99838 871 53248344
Blood pressure immeasurable 15.32 9.77 15 99836 1224 53247991
Glucose tolerance impaired 15.32 9.77 32 99819 5288 53243927
Heart rate decreased 15.31 9.77 120 99731 36827 53212388
Tremor 15.29 9.77 325 99526 125411 53123804
Device expulsion 15.29 9.77 20 99831 29793 53219422
Third stage postpartum haemorrhage 15.14 9.77 4 99847 14 53249201
Cardiac assistance device user 15.09 9.77 5 99846 44 53249171
Muscle tightness 14.90 9.77 50 99801 10971 53238244
Stress 14.90 9.77 168 99683 56916 53192299
Myocardial necrosis marker increased 14.88 9.77 17 99834 1658 53247557
Depression 14.84 9.77 247 99604 182805 53066410
Systolic dysfunction 14.77 9.77 16 99835 1471 53247744
Postpartum disorder 14.72 9.77 4 99847 16 53249199
Rash 14.70 9.77 684 99167 445507 52803708
Administration site scar 14.61 9.77 5 99846 49 53249166
Infusion site discolouration 14.53 9.77 11 99840 633 53248582
Device use issue 14.48 9.77 18 99833 1918 53247297
Platelet count decreased 14.41 9.77 131 99720 107968 53141247
Ischaemia 14.36 9.77 29 99822 4679 53244536
Epidural analgesia 14.34 9.77 5 99846 52 53249163
Pupil fixed 14.33 9.77 17 99834 1725 53247490
Hypercapnia 14.20 9.77 30 99821 4997 53244218
Liver disorder 14.20 9.77 34 99817 40121 53209094
Incision site rash 14.00 9.77 4 99847 20 53249195
Trigeminal palsy 14.00 9.77 4 99847 20 53249195
COVID-19 immunisation 13.93 9.77 9 99842 401 53248814
Hypercalcaemia 13.91 9.77 15 99836 24333 53224882
Caffeine allergy 13.84 9.77 4 99847 21 53249194
Oral herpes 13.77 9.77 77 99774 21102 53228113
Erythema 13.75 9.77 388 99463 156581 53092634
Spinal cord infarction 13.69 9.77 8 99843 297 53248918
Therapeutic product effect incomplete 13.68 9.77 108 99743 91676 53157539
Colour blindness 13.67 9.77 8 99843 298 53248917
Neurotoxicity 13.67 9.77 61 99790 15288 53233927
Foetal heart rate abnormal 13.60 9.77 10 99841 550 53248665
Smoke sensitivity 13.60 9.77 8 99843 301 53248914
Chondromalacia 13.57 9.77 8 99843 302 53248913
Irregular breathing 13.57 9.77 8 99843 302 53248913
International normalised ratio increased 13.52 9.77 45 99806 47716 53201499
Constipation 13.50 9.77 276 99575 198136 53051079
Neuroleptic malignant syndrome 13.48 9.77 3 99848 12030 53237185
Urinary tract infection 13.44 9.77 563 99288 239340 53009875
Lip disorder 13.42 9.77 14 99837 1233 53247982
Blindness 13.41 9.77 70 99781 18693 53230522
Hypomagnesaemia 13.39 9.77 16 99835 24795 53224420
Urticaria chronic 13.31 9.77 10 99841 569 53248646
No reaction on previous exposure to drug 13.30 9.77 6 99845 128 53249087
Drug hypersensitivity 13.22 9.77 615 99236 264627 52984588
Injection site ulcer 13.20 9.77 10 99841 576 53248639
Pneumonia mycoplasmal 13.10 9.77 12 99839 901 53248314
Respiratory distress 13 9.77 108 99743 33719 53215496
Sinus operation 12.99 9.77 16 99835 1689 53247526
Sinus bradycardia 12.98 9.77 58 99793 14543 53234672
Ventricular arrhythmia 12.94 9.77 24 99827 3636 53245579
Weight increased 12.91 9.77 288 99563 204279 53044936
Arthritis 12.88 9.77 103 99748 87195 53162020
Respiratory tract oedema 12.88 9.77 9 99842 457 53248758
Visual acuity reduced 12.84 9.77 79 99772 22406 53226809
Meningitis 12.84 9.77 34 99817 6547 53242668
No adverse event 12.84 9.77 121 99730 39144 53210071
Body dysmorphic disorder 12.76 9.77 7 99844 230 53248985
Forced vital capacity abnormal 12.75 9.77 4 99847 29 53249186
Orbital infection 12.75 9.77 4 99847 29 53249186
Post procedural swelling 12.72 9.77 8 99843 340 53248875
CSF pressure increased 12.69 9.77 6 99845 143 53249072
Metastases to liver 12.55 9.77 13 99838 21483 53227732
Haemorrhagic vasculitis 12.51 9.77 5 99846 78 53249137
Propionibacterium infection 12.51 9.77 4 99847 31 53249184
Anal sphincter atony 12.49 9.77 7 99844 240 53248975
Poor venous access 12.39 9.77 44 99807 9931 53239284
Genital ulceration 12.39 9.77 9 99842 486 53248729
Device issue 12.31 9.77 76 99775 21582 53227633
Plasma cell myeloma 12.29 9.77 47 99804 47827 53201388
Injection site oedema 12.25 9.77 12 99839 980 53248235
Foetal heart rate decreased 12.21 9.77 6 99845 156 53249059
Liver injury 12.20 9.77 14 99837 22089 53227126
Gamma-glutamyltransferase increased 12.19 9.77 28 99823 33527 53215688
Malabsorption from administration site 12.12 9.77 5 99846 85 53249130
Administration site rash 12.12 9.77 5 99846 85 53249130
Administration site mass 12.09 9.77 4 99847 35 53249180
Procedural anxiety 12.08 9.77 10 99841 655 53248560
Cutis laxa 12.04 9.77 6 99845 161 53249054
Accidental exposure to product by child 12.00 9.77 13 99838 1195 53248020
Cholestasis of pregnancy 11.99 9.77 13 99838 1196 53248019
Hypoxia 11.98 9.77 158 99693 55522 53193693
Transaminases increased 11.90 9.77 24 99827 30108 53219107
Diplopia 11.89 9.77 73 99778 20692 53228523
Optic atrophy 11.83 9.77 13 99838 1215 53248000
Weight decreased 11.82 9.77 342 99509 234606 53014609
Post-anoxic myoclonus 11.80 9.77 4 99847 38 53249177
Gastric infection 11.77 9.77 21 99830 3089 53246126
Quadriplegia 11.77 9.77 16 99835 1862 53247353
Bradycardia foetal 11.76 9.77 8 99843 389 53248826
Inability to afford medication 11.74 9.77 14 99837 1429 53247786
Vitamin E decreased 11.71 9.77 3 99848 9 53249206
Application site alopecia 11.71 9.77 3 99848 9 53249206
Gastrointestinal disorder 11.59 9.77 110 99741 89894 53159321
Dermatitis contact 11.57 9.77 40 99811 8912 53240303
Ascites 11.55 9.77 37 99814 39698 53209517
Mental status changes 11.50 9.77 119 99732 39452 53209763
Alanine aminotransferase increased 11.50 9.77 118 99733 94977 53154238
Cardiac arrest neonatal 11.47 9.77 5 99846 98 53249117
XIIth nerve injury 11.47 9.77 3 99848 10 53249205
Limb injury 11.47 9.77 74 99777 21336 53227879
Nail bed tenderness 11.42 9.77 7 99844 284 53248931
Overdose 11.38 9.77 273 99578 107463 53141752
Product adhesion issue 11.34 9.77 29 99822 5468 53243747
Poor quality product administered 11.33 9.77 21 99830 3180 53246035
Blood bilirubin increased 11.29 9.77 32 99819 35698 53213517
Mast cell activation syndrome 11.29 9.77 7 99844 290 53248925
Eosinophilia 11.26 9.77 14 99837 21321 53227894
COVID-19 11.24 9.77 112 99739 36776 53212439
Swelling 11.23 9.77 272 99579 190833 53058382
Device ineffective 11.22 9.77 6 99845 187 53249028
Oedema peripheral 11.19 9.77 239 99612 170548 53078667
Fear-related avoidance of activities 11.16 9.77 5 99846 105 53249110
Inflammation 11.15 9.77 62 99789 57074 53192141
Cardio-respiratory arrest 11.13 9.77 163 99688 58595 53190620
Extradural abscess 11.11 9.77 10 99841 734 53248481
Irritable bowel syndrome 11.09 9.77 43 99808 43589 53205626
Electrocardiogram U wave present 11.07 9.77 5 99846 107 53249108
Lung disorder 11.04 9.77 49 99802 47830 53201385
N-terminal prohormone brain natriuretic peptide 11.04 9.77 4 99847 47 53249168
Vascular resistance systemic decreased 11.03 9.77 5 99846 108 53249107
Eye inflammation 11.01 9.77 25 99826 4372 53244843
Normal newborn 11.00 9.77 34 99817 7145 53242070
Product distribution issue 10.99 9.77 9 99842 581 53248634
Prescribed underdose 10.93 9.77 8 99843 15659 53233556
Corneal abrasion 10.86 9.77 11 99840 935 53248280
Neutropenic sepsis 10.86 9.77 7 99844 14642 53234573
Sensitisation 10.86 9.77 13 99838 1332 53247883
Chronic kidney disease 10.86 9.77 43 99808 43327 53205888
Skin test positive 10.80 9.77 10 99841 761 53248454
Femur fracture 10.72 9.77 38 99813 39547 53209668
Epinephrine increased 10.67 9.77 3 99848 14 53249201
Poor quality sleep 10.62 9.77 62 99789 17261 53231954
Compartment syndrome 10.62 9.77 16 99835 2045 53247170
Anaphylactoid syndrome of pregnancy 10.60 9.77 4 99847 53 53249162
Haematochezia 10.60 9.77 42 99809 42316 53206899
Balance disorder 10.52 9.77 87 99764 73120 53176095
Breast cancer 10.51 9.77 52 99799 49306 53199909
Larynx irritation 10.51 9.77 5 99846 121 53249094
Arthritis fungal 10.50 9.77 3 99848 15 53249200
Arthritis bacterial 10.50 9.77 30 99821 6038 53243177
Injection site haemorrhage 10.49 9.77 74 99777 21977 53227238
Right ventricular dysfunction 10.46 9.77 14 99837 1605 53247610
Hepatic cirrhosis 10.41 9.77 11 99840 18011 53231204
Pain in jaw 10.39 9.77 40 99811 40629 53208586
Neuromuscular blockade 10.35 9.77 7 99844 337 53248878
Post procedural infection 10.35 9.77 36 99815 8045 53241170
Autonomic neuropathy 10.28 9.77 11 99840 997 53248218
Gait disturbance 10.20 9.77 223 99628 158619 53090596
Thermal burn 10.18 9.77 27 99824 5206 53244009
Tongue pruritus 10.16 9.77 8 99843 488 53248727
Rhabdomyolysis 10.10 9.77 45 99806 43878 53205337
Product administration error 10.09 9.77 72 99779 21459 53227756
Vitreous haemorrhage 10.09 9.77 15 99836 1895 53247320
Scarlet fever 10.04 9.77 5 99846 134 53249081
Injection site swelling 10.04 9.77 123 99728 42505 53206710
Melaena 10.03 9.77 25 99826 29104 53220111
Psychotic disorder 9.99 9.77 19 99832 24366 53224849
Implant site swelling 9.99 9.77 8 99843 500 53248715
Hyperkalaemia 9.99 9.77 60 99791 54196 53195019
Electrocardiogram P wave abnormal 9.98 9.77 6 99845 235 53248980
Oral pruritus 9.91 9.77 14 99837 1689 53247526
Tooth infection 9.86 9.77 53 99798 14310 53234905
Facial paralysis 9.86 9.77 52 99799 13941 53235274
Coronary artery disease 9.81 9.77 31 99820 33406 53215809
Disease recurrence 9.80 9.77 15 99836 20931 53228284
Blood glucose increased 9.77 9.77 95 99756 77266 53171949

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 541.71 10.84 1647 53559 381830 32076490
Anaphylactic reaction 403.83 10.84 365 54841 29807 32428513
Device failure 318.39 10.84 126 55080 2125 32456195
Anaphylactic shock 271.13 10.84 216 54990 14818 32443502
Anaesthetic complication 253.36 10.84 88 55118 1007 32457313
Cardiac arrest 252.68 10.84 527 54679 96249 32362071
Sinusitis 222.69 10.84 292 54914 36268 32422052
Toxic anterior segment syndrome 179.40 10.84 76 55130 1536 32456784
Chondrolysis 162.18 10.84 38 55168 78 32458242
Ventricular tachycardia 158.50 10.84 206 55000 25350 32432970
Fear 157.36 10.84 140 55066 11179 32447141
Hereditary angioedema 148.45 10.84 56 55150 824 32457496
Injury 145.31 10.84 184 55022 22061 32436259
Hypotension 135.44 10.84 723 54483 215387 32242933
Renal injury 134.62 10.84 132 55074 11923 32446397
Accidental exposure to product 129.47 10.84 125 55081 11077 32447243
Methaemoglobinaemia 126.67 10.84 72 55134 2804 32455516
Ventricular fibrillation 117.54 10.84 146 55060 17164 32441156
Stress cardiomyopathy 116.22 10.84 58 55148 1728 32456592
Anhedonia 112.33 10.84 102 55104 8362 32449958
Emotional distress 108.27 10.84 136 55070 16170 32442150
Injection site pallor 107.60 10.84 20 55186 0 32458320
Bradycardia 101.24 10.84 309 54897 71253 32387067
Unevaluable event 91.07 10.84 186 55020 33400 32424920
Lagophthalmos 90.30 10.84 23 55183 76 32458244
Ear infection 89.68 10.84 90 55116 8358 32449962
Electrocardiogram ST segment elevation 87.44 10.84 70 55136 4830 32453490
Local anaesthetic systemic toxicity 80.13 10.84 24 55182 163 32458157
Needle issue 78.71 10.84 63 55143 4346 32453974
Accidental exposure to product by child 78.21 10.84 43 55163 1568 32456752
Infusion site swelling 78.09 10.84 45 55161 1799 32456521
Infusion site pain 76.48 10.84 53 55153 2933 32455387
Bronchospasm 72.12 10.84 91 55115 10864 32447456
Drug ineffective for unapproved indication 70.88 10.84 102 55104 13810 32444510
Injection site laceration 69.84 10.84 15 55191 16 32458304
Diarrhoea 68.00 10.84 354 54852 364448 32093872
Incorrect route of product administration 67.24 10.84 91 55115 11635 32446685
Product quality issue 65.03 10.84 117 55089 19116 32439204
Cardiogenic shock 63.96 10.84 121 55085 20541 32437779
Expired product administered 63.73 10.84 48 55158 3027 32455293
Tachycardia 63.21 10.84 284 54922 78804 32379516
Arteriospasm coronary 62.30 10.84 46 55160 2814 32455506
Device use issue 62.01 10.84 22 55184 269 32458051
Upper respiratory tract infection 59.38 10.84 145 55061 29328 32428992
Injury associated with device 58.70 10.84 29 55177 845 32457475
Shock 57.77 10.84 127 55079 23987 32434333
Vasoplegia syndrome 57.65 10.84 34 55172 1420 32456900
Pain 56.30 10.84 525 54681 187031 32271289
Sinus tachycardia 55.68 10.84 100 55106 16314 32442006
Stress 55.56 10.84 124 55082 23658 32434662
General physical health deterioration 54.92 10.84 69 55137 115190 32343130
Mydriasis 54.77 10.84 61 55145 6385 32451935
Unresponsive to stimuli 54.74 10.84 135 55071 27474 32430846
Pulse absent 50.37 10.84 55 55151 5631 32452689
Infusion site extravasation 48.89 10.84 41 55165 3020 32455300
Angioedema 48.76 10.84 154 55052 36135 32422185
Hypoxic-ischaemic encephalopathy 48.40 10.84 50 55156 4804 32453516
Kounis syndrome 48.23 10.84 34 55172 1934 32456386
Interstitial lung disease 46.84 10.84 26 55180 64975 32393345
Injection site injury 45.98 10.84 16 55190 184 32458136
Decreased appetite 45.29 10.84 132 55074 160681 32297639
Infusion site pruritus 44.03 10.84 22 55184 657 32457663
Endophthalmitis 43.63 10.84 43 55163 3906 32454414
Electrocardiogram QRS complex prolonged 43.61 10.84 46 55160 4528 32453792
Wrong product administered 43.50 10.84 48 55158 4972 32453348
Completed suicide 43.42 10.84 56 55150 92461 32365859
Delayed recovery from anaesthesia 43.30 10.84 23 55183 782 32457538
Haemodynamic instability 42.56 10.84 63 55143 8748 32449572
Toxicity to various agents 42.22 10.84 475 54731 177566 32280754
Administration site pain 42.02 10.84 15 55191 187 32458133
Anaemia 41.53 10.84 217 54989 223407 32234913
Infusion site erythema 41.49 10.84 30 55176 1776 32456544
Metabolic acidosis 41.01 10.84 157 55049 40542 32417778
Anaesthetic complication neurological 40.99 10.84 17 55189 325 32457995
Accidental overdose 40.94 10.84 97 55109 19242 32439078
Trigemino-cardiac reflex 38.90 10.84 14 55192 179 32458141
Rheumatoid arthritis 38.05 10.84 14 55192 44530 32413790
Injection site pain 37.92 10.84 133 55073 32925 32425395
Multiple organ dysfunction syndrome 37.77 10.84 225 54981 69629 32388691
Cardiotoxicity 37.38 10.84 44 55162 4888 32453432
Post procedural complication 37.18 10.84 70 55136 11837 32446483
Psoriasis 36.94 10.84 16 55190 46107 32412213
Respiratory depression 36.78 10.84 74 55132 13137 32445183
Corneal reflex decreased 36.13 10.84 13 55193 166 32458154
Anxiety 35.70 10.84 282 54924 95723 32362597
Weight decreased 35.22 10.84 152 55054 164666 32293654
Injection site coldness 34.62 10.84 8 55198 15 32458305
Injection site hypoaesthesia 34.44 10.84 10 55196 60 32458260
Ventricular extrasystoles 34.25 10.84 68 55138 11958 32446362
Death 34.00 10.84 452 54754 382065 32076255
Generalised tonic-clonic seizure 33.83 10.84 94 55112 20545 32437775
Apnoea 33.70 10.84 49 55157 6694 32451626
Spinal cord infarction 32.95 10.84 14 55192 285 32458035
Medical device site laceration 32.28 10.84 6 55200 0 32458320
Urticaria 32.21 10.84 192 55014 59422 32398898
Disease progression 30.96 10.84 63 55143 86799 32371521
Cauda equina syndrome 30.87 10.84 15 55191 421 32457899
Eyelid rash 30.84 10.84 8 55198 29 32458291
Asthenia 30.62 10.84 255 54951 235689 32222631
Removal of foreign body 30.33 10.84 7 55199 13 32458307
Overdose 30.32 10.84 252 54954 86825 32371495
Pulseless electrical activity 30.28 10.84 47 55159 6803 32451517
Oculocardiac reflex 29.94 10.84 9 55197 62 32458258
Thrombocytopenia 29.74 10.84 140 55066 148159 32310161
Drug intolerance 29.65 10.84 25 55181 50210 32408110
Neutropenia 29.23 10.84 133 55073 142042 32316278
Blood pressure decreased 29.21 10.84 167 55039 50913 32407407
Procedural haemorrhage 29.14 10.84 28 55178 2465 32455855
Mean arterial pressure decreased 29.02 10.84 11 55195 164 32458156
Brain oedema 28.52 10.84 66 55140 12894 32445426
Sinus arrest 28.30 10.84 23 55183 1621 32456699
Infusion site nodule 28.03 10.84 9 55197 79 32458241
Acute kidney injury 27.79 10.84 342 54864 293126 32165194
Electrocardiogram ST segment depression 27.75 10.84 27 55179 2414 32455906
Loss of consciousness 27.03 10.84 236 54970 82471 32375849
Device malfunction 26.81 10.84 52 55154 8987 32449333
Hyperthermia malignant 26.76 10.84 24 55182 1935 32456385
Leukopenia 26.57 10.84 38 55168 60084 32398236
Laryngeal oedema 26.45 10.84 31 55175 3428 32454892
Hypoxia 26.32 10.84 165 55041 51967 32406353
Melaena 26.25 10.84 13 55193 34652 32423668
Circulatory collapse 25.98 10.84 87 55119 21038 32437282
Incorrect drug administration rate 24.68 10.84 19 55187 1238 32457082
Administration site swelling 24.66 10.84 10 55196 180 32458140
Malignant neoplasm progression 24.65 10.84 61 55145 78435 32379885
Systolic anterior motion of mitral valve 24.40 10.84 7 55199 40 32458280
Anal sphincter atony 24.17 10.84 8 55198 78 32458242
Cardiac failure congestive 23.60 10.84 70 55136 84782 32373538
Pancytopenia 23.45 10.84 78 55128 91157 32367163
Cyanosis 23.43 10.84 60 55146 12493 32445827
Hypoglycaemia 23.41 10.84 35 55171 54347 32403973
Tryptase increased 22.99 10.84 10 55196 216 32458104
Retinal artery occlusion 22.93 10.84 21 55185 1740 32456580
Dehydration 22.86 10.84 127 55079 128831 32329489
White blood cell count decreased 22.73 10.84 79 55127 91119 32367201
Pulmonary oedema 22.47 10.84 145 55061 46122 32412198
Respiratory arrest 22.45 10.84 103 55103 28805 32429515
Atrioventricular block complete 22.44 10.84 48 55158 8896 32449424
Corneal oedema 22.43 10.84 19 55187 1419 32456901
Coronary artery disease 22.38 10.84 31 55175 49675 32408645
Haemoglobin decreased 22.24 10.84 116 55090 119555 32338765
Hypersensitivity 22.19 10.84 171 55035 57587 32400733
Injection site discolouration 22.11 10.84 18 55188 1272 32457048
Oedema peripheral 22.10 10.84 109 55097 113982 32344338
Skin texture abnormal 22.10 10.84 6 55200 27 32458293
Platelet count decreased 21.90 10.84 110 55096 114481 32343839
Hyponatraemia 21.80 10.84 60 55146 74453 32383867
Neuromuscular block prolonged 21.64 10.84 12 55194 445 32457875
Hepatocellular injury 21.55 10.84 8 55198 25310 32433010
Infusion site bruising 21.52 10.84 11 55195 345 32457975
Paraplegia 21.50 10.84 25 55181 2741 32455579
Pallor 21.21 10.84 86 55120 22795 32435525
Infusion related reaction 20.99 10.84 141 55065 45458 32412862
Paraesthesia oral 20.39 10.84 29 55177 3883 32454437
Hypopyon 20.35 10.84 12 55194 501 32457819
Ophthalmoplegia 20.26 10.84 18 55188 1433 32456887
Pupil fixed 20.16 10.84 20 55186 1831 32456489
Embolia cutis medicamentosa 20.09 10.84 9 55197 209 32458111
Administration site erythema 20.00 10.84 7 55199 82 32458238
Fatigue 19.90 10.84 449 54757 350252 32108068
Throat tightness 19.85 10.84 42 55164 7724 32450596
International normalised ratio increased 19.74 10.84 33 55173 49002 32409318
Infusion site rash 19.64 10.84 10 55196 311 32458009
Left ventricle outflow tract obstruction 19.58 10.84 8 55198 147 32458173
Familial periodic paralysis 19.20 10.84 7 55199 93 32458227
Procedural complication 19.05 10.84 31 55175 4669 32453651
Agranulocytosis 19.02 10.84 8 55198 23469 32434851
Blindness 18.82 10.84 57 55149 13069 32445251
Tubulointerstitial nephritis 18.78 10.84 5 55201 19572 32438748
Procedural hypotension 18.76 10.84 15 55191 1033 32457287
Myopathy toxic 18.75 10.84 11 55195 455 32457865
Eye infection 18.69 10.84 25 55181 3160 32455160
Injection site ulcer 18.32 10.84 9 55197 259 32458061
Intracranial hypotension 18.10 10.84 9 55197 266 32458054
Vitritis 17.99 10.84 13 55193 769 32457551
Aqueous fibrin 17.82 10.84 6 55200 62 32458258
Phaeochromocytoma crisis 17.82 10.84 6 55200 62 32458258
Jaundice 17.81 10.84 19 55187 34139 32424181
Cardiac arrest neonatal 17.67 10.84 5 55201 27 32458293
Chondromalacia 17.67 10.84 5 55201 27 32458293
Malaise 17.66 10.84 204 55002 176934 32281386
Eyelid oedema 17.65 10.84 32 55174 5257 32453063
Diabetes mellitus 17.64 10.84 31 55175 45142 32413178
Anterior chamber cell 17.35 10.84 10 55196 400 32457920
Product adhesion issue 17.27 10.84 17 55189 1542 32456778
Dry gangrene 17.08 10.84 10 55196 412 32457908
Reperfusion arrhythmia 17.01 10.84 6 55200 72 32458248
Catecholamine crisis 16.69 10.84 5 55201 34 32458286
Paralysis 16.53 10.84 34 55172 6129 32452191
Retinal vasculitis 16.47 10.84 9 55197 324 32457996
Product contamination physical 16.44 10.84 5 55201 36 32458284
Allergic respiratory disease 16.44 10.84 5 55201 36 32458284
Liquid product physical issue 16.40 10.84 9 55197 327 32457993
Respiratory acidosis 16.34 10.84 28 55178 4400 32453920
Administration site irritation 16.25 10.84 4 55202 11 32458309
Administration site scar 16.14 10.84 3 55203 0 32458320
Anion gap 16.14 10.84 12 55194 742 32457578
Myalgia 16.07 10.84 77 55129 81153 32377167
Accelerated idioventricular rhythm 16.05 10.84 6 55200 86 32458234
Vitreous floaters 16.03 10.84 24 55182 3366 32454954
Areflexia 16.00 10.84 22 55184 2854 32455466
Recalled product administered 15.96 10.84 10 55196 466 32457854
Cytomegalovirus infection 15.86 10.84 12 55194 25452 32432868
Myocardial stunning 15.76 10.84 4 55202 13 32458307
Coma 15.72 10.84 125 55081 42487 32415833
Oxygen saturation decreased 15.57 10.84 137 55069 47962 32410358
Electrocardiogram T wave amplitude increased 15.56 10.84 5 55201 44 32458276
Injury corneal 15.53 10.84 4 55202 14 32458306
Tonic convulsion 15.51 10.84 13 55193 957 32457363
Vitreous disorder 15.50 10.84 6 55200 95 32458225
Nasopharyngitis 15.44 10.84 171 55035 63616 32394704
Pupillary reflex impaired 15.41 10.84 16 55190 1546 32456774
Suicide attempt 15.15 10.84 26 55180 38218 32420102
Seizure 15.09 10.84 254 54952 103600 32354720
Hepatotoxicity 15.02 10.84 7 55199 19330 32438990
Tracheitis 14.92 10.84 11 55195 671 32457649
Gait disturbance 14.89 10.84 78 55128 80330 32377990
Angina pectoris 14.75 10.84 19 55187 31407 32426913
Food allergy 14.68 10.84 13 55193 1031 32457289
Abdominal pain 14.59 10.84 173 55033 149356 32308964
Pancreatitis acute 14.48 10.84 15 55191 27320 32431000
Myocardial infarction 14.43 10.84 140 55066 125536 32332784
Plasma cell myeloma 14.29 10.84 50 55156 57564 32400756
Administration site pruritus 14.23 10.84 4 55202 21 32458299
Cholestasis 14.13 10.84 15 55191 27018 32431302
Corneal opacity 14.10 10.84 10 55196 574 32457746
Dyspnoea exertional 14.09 10.84 28 55178 38933 32419387
Gastrointestinal haemorrhage 14.09 10.84 88 55118 86794 32371526
Myocardial oedema 14.08 10.84 6 55200 123 32458197
Electrocardiogram ST-T segment depression 14.07 10.84 3 55203 3 32458317
End-tidal CO2 decreased 14.07 10.84 3 55203 3 32458317
Headache 14.02 10.84 434 54772 195763 32262557
Administration site reaction 13.96 10.84 5 55201 63 32458257
Vasoconstriction 13.92 10.84 7 55199 212 32458108
Foreign body 13.87 10.84 13 55193 1109 32457211
Visual acuity reduced 13.83 10.84 60 55146 16385 32441935
Sleep disorder 13.81 10.84 15 55191 26737 32431583
Cardiac failure 13.78 10.84 95 55111 91578 32366742
Injection site joint infection 13.64 10.84 4 55202 25 32458295
Infusion site haemorrhage 13.61 10.84 10 55196 607 32457713
Product administered at inappropriate site 13.55 10.84 16 55190 1783 32456537
Haematochezia 13.49 10.84 29 55177 39179 32419141
Gas gangrene 13.48 10.84 5 55201 70 32458250
Heart rate increased 13.46 10.84 119 55087 41709 32416611
Procedural pain 13.46 10.84 29 55177 5400 32452920
Rectal haemorrhage 13.45 10.84 27 55179 37396 32420924
Deep vein thrombosis 13.43 10.84 59 55147 63654 32394666
Pulmonary fibrosis 13.41 10.84 6 55200 16968 32441352
Intestinal haematoma 13.35 10.84 5 55201 72 32458248
Respiratory distress 13.34 10.84 104 55102 35142 32423178
Blood pressure fluctuation 13.18 10.84 9 55197 20126 32438194
Retinal vascular occlusion 13.17 10.84 6 55200 145 32458175
Medication error 13.08 10.84 74 55132 22461 32435859
Drug-induced liver injury 12.98 10.84 13 55193 24050 32434270
Expired device used 12.57 10.84 4 55202 34 32458286
Hepatitis 12.55 10.84 13 55193 23680 32434640
Myokymia 12.49 10.84 5 55201 87 32458233
Ventricular arrhythmia 12.44 10.84 27 55179 5052 32453268
Wheezing 12.44 10.84 106 55100 36768 32421552
Flushing 12.42 10.84 93 55113 31034 32427286
Nodal rhythm 12.29 10.84 14 55192 1501 32456819
Insomnia 12.28 10.84 110 55096 100238 32358082
General anaesthesia 12.26 10.84 3 55203 8 32458312
Administration related reaction 12.18 10.84 5 55201 93 32458227
Laryngeal stenosis 12.08 10.84 5 55201 95 32458225
Oral lichen planus 12.04 10.84 6 55200 178 32458142
Fall 12.01 10.84 248 54958 195953 32262367
Haematuria 11.97 10.84 42 55164 48319 32410001
Croup infectious 11.96 10.84 7 55199 288 32458032
Drug interaction 11.87 10.84 281 54925 217904 32240416
Blood pressure increased 11.86 10.84 195 55011 79159 32379161
Compartment syndrome 11.84 10.84 18 55188 2559 32455761
Anaphylactoid shock 11.78 10.84 8 55198 428 32457892
Inadequate analgesia 11.76 10.84 19 55187 2844 32455476
Open globe injury 11.76 10.84 3 55203 10 32458310
Aspirin-exacerbated respiratory disease 11.72 10.84 8 55198 432 32457888
Induration 11.71 10.84 11 55195 941 32457379
Apgar score low 11.70 10.84 11 55195 942 32457378
Transient ischaemic attack 11.69 10.84 16 55190 25778 32432542
Oesophageal obstruction 11.67 10.84 8 55198 435 32457885
Constipation 11.64 10.84 148 55058 126225 32332095
Pneumocystis jirovecii pneumonia 11.62 10.84 9 55197 18861 32439459
Brain stem syndrome 11.59 10.84 8 55198 440 32457880
Orthostatic hypotension 11.54 10.84 16 55190 25634 32432686
Blood creatinine increased 11.50 10.84 106 55100 96026 32362294
Sinus bradycardia 11.49 10.84 48 55158 12890 32445430
Optic nerve injury 11.45 10.84 5 55201 109 32458211
Spinal cord oedema 11.43 10.84 6 55200 199 32458121
Infusion site reaction 11.31 10.84 10 55196 791 32457529
Injection site extravasation 11.27 10.84 17 55189 2399 32455921
Neuromuscular blockade 11.27 10.84 6 55200 205 32458115
Seizure like phenomena 11.24 10.84 9 55197 621 32457699
Gamma-glutamyltransferase increased 11.24 10.84 22 55184 30760 32427560
Eye inflammation 11.20 10.84 15 55191 1898 32456422
Drug reaction with eosinophilia and systemic symptoms 11.20 10.84 24 55182 32461 32425859
Drug-disease interaction 11.16 10.84 7 55199 327 32457993
Penile vascular disorder 11.14 10.84 3 55203 13 32458307
Anterior spinal artery syndrome 11.14 10.84 3 55203 13 32458307
Pharyngeal oedema 11.05 10.84 30 55176 6466 32451854
Quadriplegia 11.01 10.84 14 55192 1683 32456637
Peritonitis 11.01 10.84 13 55193 22317 32436003
Chronic obstructive pulmonary disease 10.99 10.84 44 55162 48709 32409611
Nerve block 10.98 10.84 4 55202 53 32458267
Extrasystoles 10.89 10.84 22 55184 3915 32454405
Skin infection 10.88 10.84 31 55175 6871 32451449

Pharmacologic Action:

SourceCodeDescription
ATC A01AD01 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Other agents for local oral treatment
ATC B02BC09 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Local hemostatics
ATC C01CA24 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
ATC R01AA14 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Sympathomimetics, plain
ATC R03AA01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Alpha- and beta-adrenoreceptor agonists
ATC S01EA01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy
ATC R03AK01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC S01EA51 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy
FDA CS M0003647 Catecholamines
FDA MoA N0000000209 Adrenergic alpha-Agonists
FDA MoA N0000000245 Adrenergic beta-Agonists
FDA EPC N0000175552 alpha-Adrenergic Agonist
FDA EPC N0000175555 beta-Adrenergic Agonist
FDA EPC N0000175570 Catecholamine
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D009184 Mydriatics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D014662 Vasoconstrictor Agents
CHEBI has role CHEBI:24621 hormones
CHEBI has role CHEBI:35522 beta-adrenergic receptor agonist
CHEBI has role CHEBI:35523 bronchodilator agents
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35569 alpha-adrenergic receptor agonist
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:37886 adrenomimetics
CHEBI has role CHEBI:50513 mydriatics
CHEBI has role CHEBI:75771 Mus musculus metabolite

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bronchiectasis indication 12295008 DOID:9563
Bronchitis indication 32398004 DOID:6132
Anaphylaxis indication 39579001
Local anesthesia, by infiltration indication 44596000
Low blood pressure indication 45007003
Wheezing indication 56018004
Open-angle glaucoma indication 84494001 DOID:1067
Pulmonary emphysema indication 87433001
Dyspnea indication 267036007
Exacerbation of asthma indication 281239006
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Allergic Reactions indication
Administration of Local Anesthetic Nerve Block indication
Ventricular fibrillation off-label use 71908006
Asthma off-label use 195967001 DOID:2841
Local anesthesia off-label use 386761002
Cardiac arrest off-label use 410429000 DOID:0060319
Keratitis contraindication 5888003 DOID:4677
Bacterial septicemia contraindication 10001005 DOID:0040085
Sinus tachycardia contraindication 11092001
Myocardial infarction contraindication 22298006 DOID:5844
Aphakia contraindication 24010005
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypovolemia contraindication 28560003
Hypercapnia contraindication 29596007
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Retinal detachment contraindication 42059000 DOID:5327
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Stokes-Adams syndrome contraindication 46935006
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Atrial fibrillation contraindication 49436004 DOID:0060224
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Sinus bradycardia contraindication 49710005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Iritis contraindication 65074000 DOID:1406
Cerebral arteriosclerosis contraindication 65312002
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Decreased respiratory function contraindication 80954004
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Partial atrioventricular block contraindication 195039008
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Psychoneurotic personality disorder contraindication 268634009
Deficiency of cholinesterase contraindication 360607009
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Peripheral vascular disease contraindication 400047006
Anterior uveitis contraindication 410692006 DOID:1407
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Denuded skin contraindication 418242004
Thrombosis contraindication 439127006
Occlusive Vascular Disease contraindication
Regional Anesthesia for Labor Pain contraindication
Lidocaine Toxicity contraindication
Pupillary Block Glaucoma contraindication
Reduced Hepatic Blood Flow contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 12.82 acidic
pKa3 13.64 acidic
pKa4 8.71 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9833573 Nov. 23, 2024 METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
EQ 0.15MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9149579 July 19, 2025 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9149579 July 19, 2025 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
EQ 0.3MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9149579 July 19, 2025 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
EQ 0.15MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9724471 May 23, 2027 METHOD FOR CONFIRMING DOSE DELIVERY
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9724471 May 23, 2027 METHOD FOR CONFIRMING DOSE DELIVERY
EQ 0.3MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9724471 May 23, 2027 METHOD FOR CONFIRMING DOSE DELIVERY
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 10004700 Aug. 14, 2034 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 10039728 Aug. 14, 2034 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 9283197 Aug. 15, 2034 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 9283197 Aug. 15, 2034 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 9283197 Aug. 15, 2034 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
EQ 1MG BASE/ML (EQ 1MG BASE/ML) ADRENALIN PAR STERILE PRODUCTS N204200 Dec. 7, 2012 RX SOLUTION INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 9295657 March 13, 2035 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
EQ 30MG BASE/30ML (EQ 1MG BASE/ML) ADRENALIN PAR STERILE PRODUCTS N204640 Dec. 18, 2013 RX SOLUTION INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 9295657 March 13, 2035 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
EQ 0.15MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 10688244 Dec. 21, 2037 METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
EQ 0.15MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 10842938 Dec. 21, 2037 METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 10688244 Dec. 21, 2037 METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 10842938 Dec. 21, 2037 METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1D adrenergic receptor GPCR AGONIST Ki 6.66 CHEMBL CHEMBL
Alpha-1B adrenergic receptor GPCR AGONIST Ki 6.50 IUPHAR CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 6.56 DRUG MATRIX CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST Kd 6.20 CHEMBL CHEMBL
Alpha-1A adrenergic receptor GPCR AGONIST Ki 5.70 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR AGONIST Ki 6.40 DRUG MATRIX CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST Ki 6.45 DRUG MATRIX CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.40 PDSP
D(1A) dopamine receptor GPCR Kd 4.26 CHEMBL
D(2) dopamine receptor GPCR Ki 6.04 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.43 PDSP
Alpha-1D adrenergic receptor GPCR AGONIST Ki 6.30 IUPHAR
Mu-type opioid receptor GPCR Ki 5.40 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.96 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.18 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.14 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.89 CHEMBL
Adrenergic receptor beta GPCR IC50 4.54 CHEMBL
M18 aspartyl aminopeptidase Enzyme IC50 5.52 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.48 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.20 CHEMBL

External reference:

IDSource
4018034 VUID
N0000146377 NUI
D00996 KEGG_DRUG
51-42-3 SECONDARY_CAS_RN
4018032 VANDF
4018033 VANDF
4018034 VANDF
C0014563 UMLSCUI
CHEBI:28918 CHEBI
ALE PDB_CHEM_ID
CHEMBL679 ChEMBL_ID
DB00668 DRUGBANK_ID
CHEMBL1256958 ChEMBL_ID
D004837 MESH_DESCRIPTOR_UI
5816 PUBCHEM_CID
2142 INN_ID
479 IUPHAR_LIGAND_ID
YKH834O4BH UNII
203180 RXNORM
3451 MMSL
3500 MMSL
4663 MMSL
4664 MMSL
4665 MMSL
4667 MMSL
72412 MMSL
d00699 MMSL
001774 NDDF
001776 NDDF
006223 NDDF
126134000 SNOMEDCT_US
387362001 SNOMEDCT_US
50685004 SNOMEDCT_US
65502005 SNOMEDCT_US
CHEMBL3183376 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5985 INJECTION 0.15 mg INTRAMUSCULAR ANDA 24 sections
Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5986 INJECTION 0.30 mg INTRAMUSCULAR ANDA 24 sections
epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0115-1694 INJECTION 0.30 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 25 sections
epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0115-1695 INJECTION 0.15 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 25 sections
LIDOCAINE HCl and EPINEPHRINE HUMAN PRESCRIPTION DRUG LABEL 2 0264-9378 INJECTION 0.01 mg EPIDURAL ANDA 12 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0262 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 23 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0557 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 19 sections
Zorcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0830 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 29 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0898 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 23 sections
Lignospan Standard HUMAN PRESCRIPTION DRUG LABEL 2 0362-1095 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 23 sections
Lignospan Forte HUMAN PRESCRIPTION DRUG LABEL 2 0362-1096 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 23 sections
Octocaine 50 HUMAN PRESCRIPTION DRUG LABEL 2 0362-9010 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 24 sections
Vivacaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9011 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 19 sections
Vivacaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9011 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 19 sections
Prilocaine Hydrochloride with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9013 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 24 sections
Octocaine 100 HUMAN PRESCRIPTION DRUG LABEL 2 0362-9023 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 24 sections
Septocaine and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9048 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 29 sections
Septocaine and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9049 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 29 sections
LIDOCAINE HUMAN PRESCRIPTION DRUG LABEL 2 0404-6500 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 24 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6512 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 24 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6620 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6625 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 29 sections
Adrenalin HUMAN PRESCRIPTION DRUG LABEL 1 0404-9810 INJECTION 1 mg INTRAMUSCULAR NDA 15 sections
Bupivacaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9828 INJECTION, SOLUTION 5 ug INFILTRATION ANDA 12 sections
Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9856 INJECTION, SOLUTION 0.10 mg INTRAVENOUS unapproved drug other 11 sections
EPINEPHRINE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9857 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 16 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9886 INJECTION, SOLUTION 5 ug INFILTRATION ANDA 10 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9891 INJECTION, SOLUTION 10 ug INFILTRATION ANDA 10 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9896 INJECTION, SOLUTION 10 ug INFILTRATION ANDA 10 sections
MARCAINE WITH EPINEPHRINE HUMAN PRESCRIPTION DRUG LABEL 2 0404-9908 INJECTION, SOLUTION 0.01 mg INFILTRATION NDA 11 sections